{
    "organizations": [],
    "uuid": "c7523beb54dad1aae84bcd268b330ed77774f847",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-valirx-updates-on-geneice-val101/brief-valirx-updates-on-geneice-val101-idUSFWN1RW0BE",
    "ord_in_thread": 0,
    "title": "BRIEF-Valirx Updates On GENEICE & VAL101",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - ValiRx PLC:\n* ANNOUNCE POSITIVE VAL101 RESULTS, THAT ARE SHOWN TO BE EFFECTIVE IN INDUCING APOPTOSIS (PROGRAMMED CELL DEATH) IN CANCER CELL MODELS\n* RESULTS SHOW SUPERIOR APOPTOTIC EFFECT IN COMPARISON TO CURRENTLY AVAILABLE REAGENTS. Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-19T14:31:00.000+03:00",
    "crawled": "2018-04-20T12:02:52.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "valirx",
        "plc",
        "announce",
        "positive",
        "val101",
        "result",
        "shown",
        "effective",
        "inducing",
        "apoptosis",
        "programmed",
        "cell",
        "death",
        "cancer",
        "cell",
        "model",
        "result",
        "show",
        "superior",
        "apoptotic",
        "effect",
        "comparison",
        "currently",
        "available",
        "reagent",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}